Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb

• Published in: Infection and drug resistance 2023-01, Vol.16, p.3629-3638
• Main Authors: Naicker, Nikita, Rodel, Hylton, Perumal, Rubeshan, Ganga, Yashica, Bernstein, Mallory, Benede, Ntombi, Abdool Karim, Salim, Padayacthi, Nesri, Sigal, Alex, Naidoo, Kogieleum
• Format: Article
• Language: English
• Subjects: adjunctive therapy; Care and treatment; Drug resistance in microorganisms; Health aspects; host-directed therapy; Infection; inh; Macrophages; Metformin; Original Research; Tuberculosis; Type 2 diabetes
• ISSN: 1178-6973; 1178-6973
• DOI: 10.2147/IDR.S401403

Current TB treatment regimens are pathogen-directed and can be severely compromised by the development of drug resistance. Metformin has been proposed as an adjunctive therapy for TB, however relatively little is known about how metformin modulates the cellular interaction between Mtb and macrophages. We aimed to characterize how metformin modulates Mtb growth within macrophages. We utilized live cell tracking through time-lapse microscopy to better understand the biological effect of metformin in response to Mtb infection. Furthermore, the potent first-line anti-TB drug, isoniazid, was used as a comparator and as a companion drug. Metformin caused a 14.2-fold decrease in Mtb growth compared to the untreated control. Metformin combined with isoniazid controlled Mtb growth is slightly better than isoniazid alone. Metformin demonstrated the ability to regulate the cytokine and chemokine response over a 72 hour period, better than isoniazid only. We provide novel evidence that metformin controls mycobacterial growth by increasing host cell viability, and a direct and independent pro-inflammatory response to Mtb. Understanding the impact of metformin on Mtb growth within macrophages will advance our current knowledge on metformin as an adjunctive therapy, providing a new host-directed approach to TB treatment.